Price movement over the last 24 hours
Abbott Laboratories vs Abrdn Physical Platinum Shares ETF — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Abrdn Physical Platinum Shares ETF trades at $14.24. The key difference: Abbott Laboratories pays a 2.63% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals.
| ABT | PPLT | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $25.23 |
52-Week Low | $82.57 | $11.78 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
PPLT, the Aberdeen Physical Platinum Shares ETF, trades at $14.83, up 0.75% on the day, amid a bearish technical outlook with moving averages signaling sell pressure. The fund recently executed a 1-for-10 stock split effective May 18, 2026, adjusting share count without altering the underlying asset value. Key financial ratios are unavailable, as the ETF holds physical platinum, not generating traditional corporate earnings or sales.
The outlook for PPLT hinges on platinum price trends, which face headwinds from weaker industrial demand and competition from gold. Recent news highlights platinum's underperformance versus other precious metals, suggesting cautious sentiment. Risks include commodity volatility and economic cycles, while potential upside relies on a sustained rally in platinum markets.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →